Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GI Dynamics Inc (OTC: GIDYL).

Full DD Report for GIDYL

You must become a subscriber to view this report.

Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GIDYL.

About GI Dynamics Inc (OTC: GIDYL)

Logo for GI Dynamics Inc (OTC: GIDYL)

Not available


Contact Information



Current Management

  • Brian Callahan / CCO, EVP
    • Mr. Callahan, , founded and has served as president of EEC amp Associates, a global compliance consulting company providing clinical, regulatory, and quality services to domestic and international life science companies since . Mr. Callahan was the former executive vice president of clinical, quality, and regulatory affairs at Histogenics Corporation HSGX from April to September and was instrumental in raising million while working with the FDA to restart the pivotal phase III study for NeoCart. Prior to that, Mr. Callahan held positions of increasing responsibility at C.R. Bard, Inc., Johnson amp Johnson, Covidien plc, and Quintiles Inc.
  • Daniel Jeffrey Moore /
  • Dave Bruce / Principal Acct. Officer
    • Mr. Bruce, , has served as the Company s Director of Finance since April and, prior to that, as the Company s General Accounting Manager since October . Mr. Bruce served as Accounting Manager at Nutraclick LLC from April to October and, before that, as a consultant at Triton Resources from July to April , where he acted as Controller for several companies in the biotechnology industry, including GNS Healthcare, Broad Institute, Stromedix and Daktari Diagnostics. Mr. Bruce has more than years of accounting experience in the pharmaceutical, health and wellness, and fast casual restaurant industries, and holds both a BS in Accounting and an MBA with a concentration in Finance from Northeastern University.
  • Juliet Thompson / Audit Committee Member
    • Ms. Thompson has advised and raised capital for healthcare companies for more than years. Since May , Ms. Thompson has served as the chair of Premier Veterinary Group plc, a London Stock Exchangelisted provider of services to third party veterinary practices. Since March , Ms. Thompson has also served on the board of Nexstim Limited, a medical technology company listed on Nasdaq First North Finland and Sweden. Prior to that, Ms. Thompson led the European healthcare practice at Stifel Financial Corp., a diversified financial services holding company, serving as a partner from October to April . In , Ms. Thompson cofounded Code Securities, a healthcare investment banking firm that was purchased by Nomura and renamed Nomura Code Securities Limited Nomura Code in , and served as Head of Corporate Finance and as a member of the board of Nomura Code until . Ms. Thompson is also a member of the board of directors of Novacyt SA, a diagnostic company listed on Euronext. Ms. Thompson is a chartered accountant and received a Bachelor s degree in Economics from the University of Bristol. The Board believes that it will benefit from Ms. Thompson s significant experience in healthcare, entrepreneurial development and capital markets.

Current Share Structure

  • Market Cap: $369,993 - 05/11/2018
  • Issue and Outstanding: 12,333,101 - 03/15/2018


Recent Filings from (OTC: GIDYL)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018



Daily Technical Chart for (OTC: GIDYL)

Daily Technical Chart for (OTC: GIDYL)

Stay tuned for daily updates and more on (OTC: GIDYL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GIDYL)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GIDYL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GIDYL and does not buy, sell, or trade any shares of GIDYL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: